Search Bar & Filters
Found 106 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the preliminary anti-tumor effects and safety of Hemay181 in adults with advanced solid tumors who have not responded to standard treatments or have no effective standard therapy available. This open-label Phase I clinical study focuses on patients with measurable lesions that can be assessed using CT or MRI scans. The study aims to measure how well Hemay181 works by monitoring the time until tumor progression or death. Participants receive Hemay181 as an intravenous infusion once every three weeks during each treatment cycle. The study does not include a placebo group and is designed to observe the effects and safety of this drug over time. The treatment period continues until the patient experiences disease progression or death, with assessments lasting up to 100 months. During the study, participants will have regular evaluations including imaging scans to track tumor size and laboratory tests to monitor safety. Researchers will follow patients closely from the start of treatment until progression or death, with a focus on both efficacy and safety indicators. The total duration of participation varies depending on individual response and disease progression.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of TQB2102 for injection compared to a standard drug regimen in the neoadjuvant treatment of HER2-positive early or locally advanced breast cancer. This phase III randomized, open-label, multi-center trial involves about 544 patients who will be assigned to receive either TQB2102 or a combination of Trastuzumab, Pertuzumab, Docetaxel, and Carboplatin. The study aims to assess key outcomes such as total physiological complete response tpCR, breast pathological complete response bpCR, objective response rate ORR, event-free survival EFS, invasive disease-free survival IDFS, overall survival OS, and safety indicators including adverse events and immune response markers. Participants in the TQB2102 group will receive 8 cycles of intravenous infusion every 3 weeks, each cycle lasting 21 days. The comparator group will receive 6 cycles of a combination treatment with Trastuzumab, Pertuzumab, Docetaxel, and Carboplatin, also administered intravenously every 3 weeks for 21-day cycles. After completing the assigned treatment cycles, all participants will undergo breast cancer surgery. Following surgery, there will be visits to monitor disease recurrence and overall survival. Throughout the study, participants will be closely monitored with evaluations conducted up to 50 months after study start. These include assessments of tumor response by independent review and investigators, safety monitoring from consent through 40 days post last dosing or surgery, and testing for anti-drug and neutralizing antibodies. Participants will have scheduled visits for treatment administration, surgery, and follow-up to track outcomes and safety over several years.
Actively Recruiting
Researchers are investigating a combination therapy of BNT326 and pumitamig for adults with advanced or metastatic non-small cell lung cancer NSCLC that has either relapsed, progressed, or is treatment-nafve. The study includes multiple parts to find the best dose levels, assess safety and tolerability, and evaluate how well the therapy works to shrink tumors in this patient population. The trial is open-label and conducted across multiple sites, focusing on participants with confirmed advanced NSCLC where no curative treatment is available. The study consists of three parts Part 1 focuses on finding safe dose combinations of BNT326 with pumitamig Part 2a expands the dose evaluation to examine preliminary effectiveness and safety and Part 2b randomizes participants to optimize dosing and assess the contribution of each therapy component. Participants with prior treatment and those who are treatment-nafve are enrolled in different cohorts. Treatment is administered via intravenous infusion, and dose levels for Part 2b are determined based on earlier results. Participants undergo a screening period before starting treatment, which can continue for up to 24 months or until disease progression or unacceptable side effects occur. Follow-up periods monitor safety, efficacy, and long-term survival, with total involvement expected to last about 36 months unless ongoing benefit warrants extended treatment. Researchers evaluate dose-limiting toxicities, adverse events, tumor response rates, progression-free survival, and pharmacokinetics to understand treatment effects and participant outcomes.
Actively Recruiting
Researchers are evaluating BG-C137, an antibody-drug conjugate targeting FGFR2b, in people with advanced solid tumors. This study aims to assess the safety, tolerability, how the drug moves and acts in the body, and early antitumor effects. It is a phase 1ab trial involving participants with tumors expressing FGFR2b or FGFR2 gene amplification who have received prior cancer treatments. The study is sponsored by BeOne Medicines and includes two main phases dose escalation and dose expansion. The trial has three parts Phase 1a evaluates increasing doses of BG-C137 alone and then in combination with other anticancer agents to establish safe dose levels. Phase 1b further explores the recommended dose in selected patient groups. BG-C137 and anticancer agents are given intravenously or orally depending on the treatment. Participants undergo dose escalation, safety expansions, and dose confirmations to determine the best dosing for further study. Participants will be monitored regularly for side effects and response to treatment for up to about two years. Assessments include measuring adverse events, drug levels in the blood, tumor response, and immune reactions to the drug. Safety follow-up visits occur after treatment ends. Researchers will measure outcomes such as maximum tolerated dose, overall response rate, disease control, and progression-free survival. The trial involves frequent visits for treatment and assessments throughout the study period.
Actively Recruiting
Researchers are evaluating the safety, tolerability, and effectiveness of a drug called RC278 for treating locally advanced unresectable or metastatic malignant solid tumors. The study aims to find the highest safe dose, the recommended dose for further testing, and to assess how well RC278 works at that dose. This trial is a combined Phase III clinical study sponsored by RemeGen Co., Ltd., focusing on patients with solid tumors who meet specific health criteria. The study includes several stages starting with five groups receiving increasing doses of RC278 to identify the maximum tolerated dose or maximum administered dose. Following this dose-escalation, selected doses will be further tested in a randomized manner to determine the recommended Phase II dose. In the expansion phase, this dose will be studied in different types of cancers to further evaluate safety and effectiveness. RC278 is given intravenously every three weeks, and treatment continues until unacceptable side effects occur, the disease progresses, or the participant withdraws. Participants will be monitored for up to 24 months to track dose-limiting toxicities, adverse events, and tumor response using standard criteria. Assessments include imaging to measure tumor size, safety evaluations, and pharmacokinetic testing. The study collects data on how well participants tolerate the drug and how their tumors respond. Follow-up continues throughout the study to ensure participant safety and to gather comprehensive information on the drugs effects.
Actively Recruiting
Researchers are conducting a Phase 12a clinical trial to evaluate the safety and tolerability of DB-1311BNT324 in adults with advanced solid tumors that have progressed after standard treatments or have no available standard options. The trial aims to find the maximum tolerated dose and recommended dose for further study, as well as explore preliminary antitumor activity in selected cancers including prostate cancer. The study is multicenter, open-label, and includes a drug-drug interaction sub-study to assess the effects of other medications on DB-1311. In Phase 1, participants receive escalating single doses of DB-1311BNT324 every three weeks to determine safety and optimal dosing. Phase 2a expands dosing to confirm safety and explore effectiveness of DB-1311 given alone or combined with hormone therapies such as enzalutamide or abiraterone in prostate cancer. Treatment cycles are repeated every 21 days via intravenous infusion. Some participants receive additional oral medications to study interactions. The trial includes various cohorts with different tumor types and prior treatment histories. Participants undergo multiple assessments including safety labs, vital signs, ECGs, heart function tests, and performance status evaluations throughout treatment and for about one year after. Tumor response is measured using standard criteria, along with pharmacokinetic and immunogenicity tests. Researchers monitor adverse events and serious events continuously. The total participation lasts up to approximately one year post-treatment to evaluate safety, dosing, and preliminary outcomes.
Actively Recruiting
Researchers are evaluating the drug WS016 to treat hyperkalemia, a condition characterized by high potassium levels in the blood. This open-label Phase 3 clinical trial includes two phases a corrective phase aiming to reduce potassium levels within 24 to 72 hours, followed by a maintenance phase to keep potassium levels normal over a 12-month period in participants who meet specific criteria after the first phase. Participants first receive oral doses of WS016 12 grams three times daily during the corrective phase. Those whose potassium levels normalize enter the maintenance phase, receiving WS016 once daily at 12 grams, with dose adjustments based on potassium levels over the following 12 months. This study evaluates the long-term safety and effectiveness of WS016 in maintaining normal potassium levels. Throughout the study, participants undergo regular blood tests to monitor potassium levels and safety assessments during both phases. Researchers measure the percentage of participants maintaining potassium at or below 5.0 mmolL during the maintenance phase. Adverse events and changes in potassium are tracked closely. The total participation may last over a year, including both treatment phases and follow-up assessments.
Actively Recruiting
Researchers are evaluating FWD1802, a drug being studied for patients with estrogen receptor-positive ER, human epidermal growth factor receptor 2-negative HER2- advanced breast cancer that cannot be removed by surgery or has spread to other parts of the body. This phase III study aims to find the best dose of FWD1802 and assess its safety, tolerability, and effect on tumors, especially in patients whose cancer has specific ESR1 mutations. The study is multicenter, open-label, and includes patients with locally advanced or metastatic breast cancer. The study has three parts Phase I Part A is a dose-escalation phase where up to 27 patients receive increasing doses of FWD1802 tablets, starting with a single dose followed by daily dosing in 28-day cycles. Phase I Part B is a dose-expansion phase exploring 2 to 4 selected dose levels in up to 10 patients per dose to study pharmacokinetics and confirm the recommended dose for Phase II. Phase II focuses on up to 60 patients with ESR1 mutations receiving one or two dose levels to evaluate FWD1802s anti-tumor efficacy and safety. Treatment may continue up to two years or longer if beneficial and agreed upon. Participants will undergo screening including mutation testing and must meet health criteria to join. During treatment, they will receive FWD1802 daily and have blood tests to monitor mutations and drug effects. The study measures safety, drug levels in the body, tumor response, and patient outcomes over about two years. Follow-up includes monitoring for side effects, response to treatment, and disease progression. The trial is designed to gather detailed information about FWD1802s use in this breast cancer type and mutation status.
Actively Recruiting
Researchers are evaluating a phase IbII study of ATG-022 plus pembrolizumab with or without chemotherapy in participants who have Claudin 18.2-positive, HER2-negative, PD-L1 positive advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. The study targets adults who have either progressed after prior systemic therapy or who have not received any systemic therapy for their condition. The study aims to assess the combination treatments for this specific cancer type. Participants receive either ATG-022 plus pembrolizumab alone or combined with chemotherapy CAPOX regimen, including capecitabine and oxaliplatin. The ATG-022 and pembrolizumab drugs are given every 21 days as one cycle, while the CAPOX chemotherapy is administered in 3-week cycles for up to 8 cycles. The study begins with the evaluation of ATG-022 plus pembrolizumab alone, and the addition of chemotherapy will start based on clinical data from this initial group. Throughout the study, participants undergo tumor testing, imaging, and clinical evaluations to measure safety and effectiveness. Researchers monitor adverse events, dose-limiting toxicities, and treatment responses for up to 12 months after enrollment. Blood samples are collected to analyze drug concentrations. Participants are closely followed to assess overall response, duration of response, and progression-free survival, ensuring comprehensive safety and treatment effect data collection.
Actively Recruiting
Researchers are evaluating the safety, effectiveness, and how the body processes INT-210 capsules in adults with active ulcerative colitis UC. This randomized, open-label study focuses on participants aged 18 to 75 years diagnosed with active UC, aiming to gather detailed information on the drugs pharmacokinetics and pharmacodynamics while monitoring treatment safety. Participants will receive oral INT-210 capsules in one of two doses 200 mg twice daily or 400 mg twice daily, starting from Day 1 of a 12-week treatment period. The study is designed to compare these two dosing regimens in parallel groups to assess their impact on UC symptoms and drug behavior in the body. During the study, participants will undergo various assessments including laboratory tests to monitor safety, clinical evaluations to measure remission and response rates, and pharmacokinetic sampling up to Day 85. Safety follow-up continues through Day 92 to track adverse events and important clinical parameters. Overall, participants can expect regular visits and monitoring throughout the treatment and follow-up phases lasting approximately 3 months.
1-10 of 106
1